Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
Globenewswire·2025-09-02 13:00
Ethereum to Enhance Multi-Faceted Corporate Strategy of Cryptocurrency Exposure, Pharmaceutical Drug Development & Asset AcquisitionMELBOURNE, Australia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a plan to acquire $100 million of Ethereum over the next 12 months. The asset purchase of Ethereum will enhance a ...